Benign anorectal disorders are often distressing, debilitating, and add significantly to the health care burden. This article summarizes a presentation on benign anorectal disorders by Damanpreet K. Grewal,...
The researchers discussed the use of risankizumab induction therapy and its ability to treat symptoms that greatly affect the lives of patients with Crohn disease. The research was presented at ACG 2022.
...
According to a recent study, subcutaneous maintenance dosing of risankizumab at 52 weeks is effective and well-tolerated in patients with moderate-to-severe Crohn disease who had a delayed response to...
The authors of a new study presented at the ACG 2019 Annual Meeting evaluated data of more than 200 adult gastroenterology patients to characterize patients with avoidant/restrictive food intake disorder.
...
